Last update
3/11/2026
Reviewed By
Infographics
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.2
USERS' SCORE
Good
Based on 14 Reviews
8.2
Supplement Facts
Serving Size: 1 Veggie Capsule
Amount Per Serving
%DV
Alpha-Lipoic acid
300 mg
†
Benfotiamine
150 mg
†
Top Medical Research Studies
7
Benfotiamine showed no significant benefits
We conducted a comprehensive study to explore the effects of benfotiamine on diabetic sensorimotor polyneuropathy (DSPN) in type 2 diabetes patients. In a randomized double-blind trial involving 60 participants, we compared benfotiamine treatment to a placebo over 12 months.
The main focus was on changes in corneal nerve fiber length, along with various other clinical measures. Unfortunately, the results did not show significant benefits from benfotiamine treatment in improving the condition compared to the placebo.
The main focus was on changes in corneal nerve fiber length, along with various other clinical measures. Unfortunately, the results did not show significant benefits from benfotiamine treatment in improving the condition compared to the placebo.
Read More
2
Benfotiamine showed no significant benefit
We explored how benfotiamine affects the formation of advanced glycation endproducts and markers of endothelial dysfunction and inflammation in patients with type 2 diabetes and nephropathy.
Through a rigorous trial design, participants were divided into two groups—one receiving benfotiamine and the other a placebo.
After 12 weeks, the results showed no significant differences in the targeted health markers between the two groups.
This suggests that benfotiamine may not have a meaningful impact on these diabetes-related complications.
Through a rigorous trial design, participants were divided into two groups—one receiving benfotiamine and the other a placebo.
After 12 weeks, the results showed no significant differences in the targeted health markers between the two groups.
This suggests that benfotiamine may not have a meaningful impact on these diabetes-related complications.
Read More
We investigated the long-term effects of benfotiamine supplementation on patients with type 1 diabetes. In a double-blind study, 67 participants were split between a benfotiamine group and a placebo group for 24 months.
While we noticed a significant rise in thiamine levels in those taking benfotiamine, there were no meaningful improvements in peripheral nerve function or inflammatory markers.
Overall, our findings indicate that high-dose benfotiamine supplementation does not benefit peripheral nerve function or inflammation in type 1 diabetes patients.
While we noticed a significant rise in thiamine levels in those taking benfotiamine, there were no meaningful improvements in peripheral nerve function or inflammatory markers.
Overall, our findings indicate that high-dose benfotiamine supplementation does not benefit peripheral nerve function or inflammation in type 1 diabetes patients.
Read More
Most Useful Reviews
9
Effective for diabetes
2 people found this helpful
I have diabetes and find this product has helped me significantly.
Read More
9
Nerve protection
1 people found this helpful
This product is wonderful and useful for those with diabetes. It protects nerves from damage and feels like a gift from God.
Read More
9
Cost-effective supplement
7 people found this helpful
This is the only product that combines both Benfotiamine and ALA, saving me money. Both ingredients greatly assist with diabetes management. I find this product effective and affordable.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.2
- All Researches
9
We investigated the treatment of diabetic peripheral neuropathy (DPN), a common complication affecting many diabetes patients. Standard approaches focus on lifestyle changes and diabetes control, but symptomatic pain relief is often insufficient. Fortunately, recent studies highlight promising options like benfotiamine, which has shown effectiveness in reducing symptoms over time. The NATHAN 1 trial pointed to notable improvements in nerve function after four years. These findings suggest that additional, well-researched therapies could enhance DPN management and improve patient outcomes. Long-term studies are still needed to confirm their full potential.
Read More
9
We explored a case involving a female child diagnosed with neonatal diabetes mellitus and Thiamine Responsive Megaloblastic Anaemia (TRMA). After being treated with benfotiamine, we saw a remarkable improvement in her blood parameters and a significant reduction in insulin requirements.
She has been in remission for two years, highlighting benfotiamine as a valuable treatment option for managing TRMA. This case suggests that benfotiamine could be a beneficial alternative when traditional thiamine treatments are unavailable.
She has been in remission for two years, highlighting benfotiamine as a valuable treatment option for managing TRMA. This case suggests that benfotiamine could be a beneficial alternative when traditional thiamine treatments are unavailable.
Read More
9
We examined how benfotiamine affects endothelial cell survival in high glucose conditions, particularly looking at a key enzyme called PP2A. In our research, we found that elevated glucose levels lead to increased activity of PP2A, contributing to cell death. However, when we introduced benfotiamine, it effectively inhibited this enzyme's activation, and consequently, reduced cell death. This suggests that benfotiamine could be beneficial for managing diabetic complications by protecting these cells from damage caused by high blood sugar.
Read More
8
We investigated how d-ribose influences HbA1c, a key marker for diabetes management. Our research showed that d-ribose reacts with hemoglobin, contributing to elevated HbA1c levels. We observed that administering benfotiamine, which activates an important enzyme, led to a significant decrease in both d-ribose and HbA1c. Notably, T2DM patients with high HbA1c also had increased urinary d-ribose, suggesting a possible connection between the two.
These findings indicate that d-ribose plays a role in HbA1c formation, highlighting the need for further studies to explore its impact on type 2 diabetes.
These findings indicate that d-ribose plays a role in HbA1c formation, highlighting the need for further studies to explore its impact on type 2 diabetes.
Read More
8
We investigated how benfotiamine affects diabetes-related cell death in mice with ischemic limbs. By using a special imaging technique, we could see how well this treatment worked.
Our findings showed that benfotiamine improved blood flow in these limbs and reduced the markers of cell death. The imaging results matched well with biological indicators of apoptosis.
While promising, this research suggests more studies are needed to fully understand benfotiamine's potential in treating diabetes-related complications.
Our findings showed that benfotiamine improved blood flow in these limbs and reduced the markers of cell death. The imaging results matched well with biological indicators of apoptosis.
While promising, this research suggests more studies are needed to fully understand benfotiamine's potential in treating diabetes-related complications.
Read More
User Reviews
USERS' SCORE
Good
Based on 14 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Effective for diabetes
2 people found this helpful
I have diabetes and find this product has helped me significantly.
Read More
9
Nerve protection
1 people found this helpful
This product is wonderful and useful for those with diabetes. It protects nerves from damage and feels like a gift from God.
Read More
9
Cost-effective supplement
7 people found this helpful
This is the only product that combines both Benfotiamine and ALA, saving me money. Both ingredients greatly assist with diabetes management. I find this product effective and affordable.
Read More
7.5
Supports diabetes management
3 people found this helpful
I can confidently say that this product helps to manage the effects and complications of type 2 diabetes.
Read More
9
Effective blood sugar control
2 people found this helpful
Just what the doctor ordered. My doctor advised me to take Benfotiamine 150 + Alpha-Lipoic Acid to manage my blood sugar levels. It works brilliantly alongside my diabetes medications and other supplements like Chromium.
Read More
Frequently Asked Questions
7.5
Improved sugar readings
1 people found this helpful
I've been using this for type 2 diabetes alongside Metformin. My research indicates that diabetes medications may deplete vitamin B1, and since I added this to my regimen, my morning sugar readings have generally improved.
9
We investigated the treatment of diabetic peripheral neuropathy (DPN), a common complication affecting many diabetes patients. Standard approaches focus on lifestyle changes and diabetes control, but symptomatic pain relief is often insufficient. Fortunately, recent studies highlight promising options like benfotiamine, which has shown effectiveness in reducing symptoms over time. The NATHAN 1 trial pointed to notable improvements in nerve function after four years. These findings suggest that additional, well-researched therapies could enhance DPN management and improve patient outcomes. Long-term studies are still needed to confirm their full potential.
7
Benfotiamine showed no significant benefits
We conducted a comprehensive study to explore the effects of benfotiamine on diabetic sensorimotor polyneuropathy (DSPN) in type 2 diabetes patients. In a randomized double-blind trial involving 60 participants, we compared benfotiamine treatment to a placebo over 12 months.
The main focus was on changes in corneal nerve fiber length, along with various other clinical measures. Unfortunately, the results did not show significant benefits from benfotiamine treatment in improving the condition compared to the placebo.
The main focus was on changes in corneal nerve fiber length, along with various other clinical measures. Unfortunately, the results did not show significant benefits from benfotiamine treatment in improving the condition compared to the placebo.
8
We explored how benfotiamine, a special form of vitamin B1, can impact diabetes treatment. This compound helps reduce harmful substances called advanced glycation end products (AGEs), which are linked to complications like nerve and kidney damage in diabetes. By boosting thiamine levels in the body, benfotiamine may lower the accumulation of AGEs, thereby alleviating inflammation and stress that worsen diabetes. However, while it shows promise for certain diabetes-related complications, we found mixed results regarding its overall effectiveness.
2
Benfotiamine showed no significant benefit
We explored how benfotiamine affects the formation of advanced glycation endproducts and markers of endothelial dysfunction and inflammation in patients with type 2 diabetes and nephropathy.
Through a rigorous trial design, participants were divided into two groups—one receiving benfotiamine and the other a placebo.
After 12 weeks, the results showed no significant differences in the targeted health markers between the two groups.
This suggests that benfotiamine may not have a meaningful impact on these diabetes-related complications.
Through a rigorous trial design, participants were divided into two groups—one receiving benfotiamine and the other a placebo.
After 12 weeks, the results showed no significant differences in the targeted health markers between the two groups.
This suggests that benfotiamine may not have a meaningful impact on these diabetes-related complications.
References
- Ziegler D. Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2023;206 Suppl 1:110764. 10.1016/j.diabres.2023.110764
- Bönhof GJ, Sipola G, Strom A, Herder C, Strassburger K, et al. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open. 2022;12:e057142. 10.1136/bmjopen-2021-057142
- Dalwadi P, Joshi AS, Thakur DS, Bhagwat NM. Neonatal diabetes mellitus: remission induced by novel therapy. BMJ Case Rep. 2019;12. 10.1136/bcr-2018-228806
- Chen X, Su T, Chen Y, He Y, Liu Y, et al. d-Ribose as a Contributor to Glycated Haemoglobin. EBioMedicine. 2017;25:143. 10.1016/j.ebiom.2017.10.001
- Jung KH, Lee JH, Park JW, Paik JY, Quach CH, et al. Annexin V imaging detects diabetes-accelerated apoptosis and monitors the efficacy of benfotiamine treatment in ischemic limbs of mice. Mol Imaging. 2014;13:1. PubMed
- Nacitarhan C, Minareci E, Sadan G. The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes. Exp Clin Endocrinol Diabetes. 2014;122:173. 10.1055/s-0033-1363977
- Kousar S, Sheikh MA, Asghar M. Antiglycation activity of thiamin-HCl and benfotiamine in diabetic condition. J Pak Med Assoc. 2012;62:1033. PubMed
- Katare R, Oikawa A, Cesselli D, Beltrami AP, Avolio E, et al. Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res. 2013;97:55. 10.1093/cvr/cvs291
- Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One. 2012;7:e40427. 10.1371/journal.pone.0040427
- Tarallo S, Beltramo E, Berrone E, Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol. 2012;49 Suppl 1:S141. 10.1007/s00592-012-0390-5
- Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. 2012;35:1095. 10.2337/dc11-1895
- Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011;6:260. PubMed
- Du Y, Kowluru A, Kern TS. PP2A contributes to endothelial death in high glucose: inhibition by benfotiamine. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1610. 10.1152/ajpregu.00676.2009
- Winkler G, Kempler P. [Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy]. Orv Hetil. 2010;151:971. 10.1556/OH.2010.28898
- Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. 2010;53:1506. 10.1007/s00125-010-1722-z
- Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. 2010;61:482. 10.1016/j.phrs.2010.02.008
- Csiha S, Hernyák M, Molnár Á, Lőrincz H, Katkó M, et al. Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy. Biomedicines. 2025;13. 10.3390/biomedicines13020438
- Zoheir KMA, Ali NI, Ashour AE, Kishta MS, Othman SI, et al. Lipoic acid improves wound healing through its immunomodulatory and anti-inflammatory effects in a diabetic mouse model. J Diabetes Metab Disord. 2025;24:56. 10.1007/s40200-025-01559-y
- Lu Q, Tang X, Tao B, Huang K, Li K, et al. Multifunctional hyaluronic acid microneedle patch enhances diabetic wound healing in diabetic infections. Int J Biol Macromol. 2025;296:139685. 10.1016/j.ijbiomac.2025.139685
Data last updated:
